Pharvaris NV expected to post a loss of 56 cents a share - Earnings Preview
Brief: Pharvaris NV Files For Mixed Shelf Offering Size Not Disclosed
Brief: Pharvaris Appoints David Nassif, J.D., As CFO
Pharvaris NV expected to post a loss of 53 cents a share - Earnings Preview
Pharvaris rises as FDA lifts clinical hold of hereditary disease drug
Brief: Pharvaris NV Announces FDA Lifting Of Clinical Hold Of Deucrictibant For The Prophylactic Treatment Of Hae Attacks
Founder Jochen Knolle To Transition As Strategic Advisor To CEO
U.S. STOCKS ON THE MOVE-Vera Bradley, Shake Shack, 2seventy Bio
U.S. STOCKS ON THE MOVE-Citigroup, Regeneron, Ormat
U.S. STOCKS ON THE MOVE-Coya, AeroVironment, Cleveland-Cliffs
Brief: Pharvaris NV Pricing Of Underwritten Offering Of 11.1 Million Ordinary Shares At $24.00 Per Share
Brief: Pharvaris Announces Positive Top-Line Phase 2 Data From The Chapter-1 Study Of Deucrictibant For The Prophylactic Treatment Of HAE Attacks
Pharvaris jumps as skin disease drug meets mid-stage study goal
Pharvaris up after Wedbush initiates stock coverage with 'outperform' rating
Brief: Pharvaris NV Files For Offering Of Up To 6.95 Mln Ordinary Shares By Selling Securityholders
Brief: Pharvaris N.V. reports Q2 EPS EUR -0.63
Pharvaris up as FDA lifts hold on skin disease drug study
Brief: Pharvaris NV Reports Quarterly Basic And Diluted Loss Per Share Of EUR 0.67
Brief: Pharvaris Says Deucrictibant Data Highlighted In Multiple Presentations At C1-Inhibitor Deficiency And Angioedema Workshop